Skip to main content
SpringerLink
Log in

Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells

  • Original Articles
  • Topoisomerase, Acridine, Intercalation, Lewis Lung
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The cytotoxicity of a class of compounds related to the topoisomerase-II poison amsacrine was investigated against plateau-phase murine Lewis lung carcinoma cells (LLTC), HCT-8 human colon carcinoma cells and other cell lines. MethylN-[4-(9-acridinylamino)-2-methoxy-phenyl]carbamate hydrochloride and the corresponding demethoxy compound, which contain a methylcarbamate instead of the methylsulphonylamino group, manifested relatively high cytotoxic activity against plateau-phase cells as measured by clonogenic survival. The concentration of drug required for a given cytotoxic effect on plateau-phase cells was about 2 times higher than that required for an equitoxic effect on actively proliferating cells. In contrast, at least 5 times more amsacrine, doxorubicin or etoposide was needed for an equitoxic effect on plateau-phase cells. Cells taken directly from subcutaneous LLTC tumours and exposed to drugs displayed the same differential drug sensitivity to the carbamate compounds, suggesting that the plateau-phase cells provide an appropriate model for cells growing in vivo. The greater cytotoxicity of the carbamate drugs was shown to depend critically on the provision of an energy source such as glucose, suggesting that nutrient starvation both in plateau-phase cells and in tumours induced a glucose-sensitive resistance mechanism. It is suggested that the carbamate analogues of amsacrine recognize a form of topoisomerase II, possibly topoisomerase IIβ, the activity of which increases relative to that of topoisomerase IIα in non-cycling cells, and might be used to devise new strategies for the treatment of solid tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA (1987) Potential antitumor agents. 50. In vivo solid tumor activity of derivatives ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30: 664–669

    Google Scholar 

  2. Baguley BC (1991) DNA intercalating anti-tumour agents. Anticancer Drug Des 6: 1–35

    Google Scholar 

  3. Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, Wilson WR (1984) Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine,N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)-phenyl-amino]-4-acridinecarboxamide. Cancer Res 44: 3245–3251

    Google Scholar 

  4. Baguley BC, Finlay GJ, Wilson WR (1986) Cytokinetic resistance of Lewis lung carcinoma to cyclophosphamide and the amsacrine derivative CI-921. In: Hall TC (ed) Cancer drug resistance (Progress in clinical and biological research series, 23) Alan R Liss, New York, pp 47–61

    Google Scholar 

  5. Baguley BC, Holdaway KM, Fray LM (1990) Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst 82: 398–402

    Google Scholar 

  6. Baguley BC, Finlay GJ, Ching LM (1992) Resistance mechanisms to topoisomerase poisons — the application of cell culture methods. Oncology Res 4: 267–274

    Google Scholar 

  7. Beck WT (1987) The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879–2887

    Google Scholar 

  8. Beck WT, Cirtain MC, Danks MK, Felsted RI, Safa AR, Wolverton JS, Suttle DP, Trent JM (1987) Pharmacological, molecular, and cytogenetic analysis of ‘atypical’ multidrug-resistant human leukemic lines. Cancer Res 47: 5455–5460

    Google Scholar 

  9. Cain BF, Atwell GJ (1974) The experimental antitumour properties of three congeners of the acridinyl methanesulphonanilide (AMSA) series. Eur J Cancer 10: 539–549

    Google Scholar 

  10. Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK (1989) Characterization and immunological identification of cDNA clones encoding 2 human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 86: 9431–9435

    Google Scholar 

  11. Colofiore JR, Ara G, Berry D, Belli JA (1982) Enhanced survival of Adriamycin-treated Chinese hamster cells by 2-deoxy-d-glucose and 2,4-dinitrophenol. Cancer Res 42: 3934–3940

    Google Scholar 

  12. Downes CS, Ord MJ, Mullinger AM, Collins ARS, Johnson RT (1985) Novobiocin inhibition of DNA excision repair may occur through effects on mitochondrial structure and ATP metabolism, not on repair topoisomerases. Carcinogenesis 6: 1343–1352

    Google Scholar 

  13. Drake FH, Zimmerman JO, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR Johnson RK, Crooke ST, Mirabelli CK (1987) Purification of topoisomerase II from amascrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem 262: 16739–16747

    Google Scholar 

  14. Drewinko B, Patchen M, Yang L-Y, Barlogie B (1981) Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res 41: 2328–2333

    Google Scholar 

  15. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 351–375

    Google Scholar 

  16. Finlay GJ, Baguley BC (1989) Selectivity ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. Eur J Cancer Clin Oncol 25: 271–277

    Google Scholar 

  17. Finlay GJ, Baguley BC (1990) Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II. Eur J Cancer 26: 586–589

    Google Scholar 

  18. Finlay GJ, Wilkson WR, Baguley BC (1986) Comparison of in vitro activity of cytotoxic drugs toward human carcinoma and leukaemia cell lines. Eur J Cancer Clin Oncol 22: 655–662

    Google Scholar 

  19. Finlay GJ, Wilson WR, Baguley BC (1987) Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures. Br J Cancer 56: 755–762

    Google Scholar 

  20. Finlay GJ, Marshall E, Matthews JHL, Paull KD, Baguley BC (1993) In vitro assessment ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 31: 401–406

    Google Scholar 

  21. Goldwater PN, Flynn KE, Gunn CS, Baguley BC (1985) 9-Anilinoacridines: novel compounds active against herpes simplex virus. Chem Biol Interact 54: 377–382

    Google Scholar 

  22. Granzen B, Graves DE, Baguley BC, Danks MK, Beck WT (1992) Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase-II or P-glycoprotein. Oncol Res 4: 489–496

    Google Scholar 

  23. Heck MM, Earnshaw WC (1986) Topoisomerase II: specific marker for cell proliferation. J Cell Biol 103: 2569–2581

    Google Scholar 

  24. Holdaway KM, Finlay GJ, Baguley BC (1992) Relationship of cell cycle parameters to in vitro and in vivo chemosensitivity for a series of Lewis lung carcinoma lines. Eur J Cancer 28A: 1427–1431

    Google Scholar 

  25. Holden JA, Rolfson DH, Wittwer CT (1992) The distribution of immunoreactive topoisomerase-II protein in human tissues and neoplasms. Oncol Res 4: 157–166

    Google Scholar 

  26. Hughes CS, Shen JW, Subjeck JR (1989) Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res 49: 4452–4454

    Google Scholar 

  27. Murren JR, Hait WN (1992) Why haven't we cured multidrug resistant tumors? Oncol Res 4: 1–6

    Google Scholar 

  28. Per SR, Mattern MR, Mirabelli CK, Drake FH, Johnson RK (1987) Characterization of a subline of P388 leukaemia resistant to amsacrine: evidence of altered topoisomerase II function. Mol Pharmacol 32: 17–25

    Google Scholar 

  29. Qian X, Beck WT (1990) Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines. Cancer Res 50: 1132–1137

    Google Scholar 

  30. Shen J, Hughes C, Chao C, Dai J, Bartels C, Gessner T, Subjeck J (1987) Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells Proc Natl Acad Sci USA 84: 3278–3282

    Google Scholar 

  31. Shibuya ML, Buddenbaum WE, Don AL, Utsumi H, Suciu D, Kosaka T, Elkind MM (1991) Amsacrine-induced lesions in DNA and their modulation by novobiocin and 2,4-dinitrophenol. Cancer Res 51: 573–580

    Google Scholar 

  32. Snow K, Judd W (1991) Characterisation of Adriamycin-resistant and amsacrine-resistant human leukaemic T-cell lines. Br J Cancer 63: 17–28

    Google Scholar 

  33. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M (1991) Increased phosphorylation of DNA topoisomerase II in etoposideresistant mutants of human cancer KB cells. Cancer Res 51: 3951–3957

    Google Scholar 

  34. Tannock I (1978) Cell kinetics and chemotherapy a critical review. Cancer Treat Rep 62: 1117–1133

    Google Scholar 

  35. Utsumi H, Shibuya ML, Kosaka T, Buddenbaum WE, Elkind MM (1990) Abrogation by novobiocin of cytotoxicity due to the topoisomerase II inhibitor amsacrine in Chinese hamster cells. Cancer Res 50: 2577–2581

    Google Scholar 

  36. Wilkoff LJ, Dulmadge E, Chopra DP (1980) Viability of cultured lewis lung cell populations exposed to β-retinoic acid (40753). Proc Soc Exp Biol Med 163: 233–236

    Google Scholar 

  37. Zwelling LA, Mitchell MJ, Satitpunwaycha P, Mayes J, Altschuler E, Hinds M, Baguley BC (1992) Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or amsacrine-resistant forms of topoisomerase-II — use of computer simulations in new drug development. Cancer Res 52: 209–217

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research Laboratory, University of Auckland School of Medicine, Private Bag 92019, Auckland, New Zealand

    Graeme J. Finlay, Karen M. Holdaway & Bruce C. Baguley

Authors
  1. Graeme J. Finlay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen M. Holdaway
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruce C. Baguley
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This research was supported by the Cancer Society of New Zealand, by its Auckland Division, and by the Health Research Council of New Zealand.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finlay, G.J., Holdaway, K.M. & Baguley, B.C. Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells. Cancer Chemother. Pharmacol. 34, 159–165 (1994). https://doi.org/10.1007/BF00685934

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685934

Keywords

Search

Navigation